Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Intellia Therapeutics, Inc. (NTLA) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 12,059.22 | 865.75 | 127.41 | 229.37 | 6.31 | 0.00 | 22.3153 | -0.82 | -0.0263 | -18.6295 | -0.08 | -0.07 | 6.9468 | - - | ||
| Maximum | - - | - - | - - | 444,129.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.02 | 1,336.3467 | 6.70 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -6,783.00 | -56,335.00 | -2,077.00 | 0.00 | -164.8536 | -57.22 | -16.7400 | -1,444.7800 | -1.56 | -12.64 | 0.0007 | - - | ||
| Intellia Therapeutics, Inc. NTLA | 13.80 | 0.68 5.18% | 3,520 vs. 2,168 | 1,405.00 | 28.00 | -107.00 | -123.00 | -1,765.00 | -1.1200 | -6.0491 | 0.0000 | 0.9132 | -3.7130 | -0.1037 | -0.0853 | 8.4537 | 101.00 | ||
| CRISPR Therapeutics AG CRSP | 46.29 | -0.97 -2.05% | 2,088 vs. 1,262 | 3,951.00 | 0.00 | -116.00 | 109.00 | -1,116.00 | -1.4300 | -11.9580 | 0.0000 | -101.7758 | -231.3313 | -0.0559 | -0.0478 | 17.7168 | 85.00 | ||
| Vertex Pharmaceuticals Incorporated VRTX | 450.37 | -0.86 -0.19% | 1,492 vs. 1,118 | 115,983.00 | 2,687.00 | 1,099.00 | 1,058.00 | 11,242.00 | 4.2600 | 24.6835 | 0.0000 | 0.8725 | 0.4092 | 0.0593 | 0.0460 | 3.1520 | 257.00 | ||
| Beam Therapeutics Inc. BEAM | 23.58 | -0.91 -3.72% | 1,009 vs. 960 | 1,952.00 | 7.00 | -98.00 | -102.00 | -1,288.00 | -1.2100 | -6.7607 | 0.0000 | 0.2671 | -13.3157 | -0.1080 | -0.0726 | 5.8464 | 82.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.